Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin in Severe Acute Pancreatitis
NCT01132521Phase 4Suspended
- Sponsor
- Guangdong Techpool Bio-pharma
- Start
- Jun 2010
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute pancreatitis (AP) comparing ulinastatin group with placebo group (2 arms). Primary endpoints: multiple organ dysfunction score at 8 days and onset of (multiple) organ failure after randomized at 8 days. Started Jun 2010; status: suspended.
02
Drugs
ulinastatin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT01132521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132521.